Komori
ASKA Pharmaceutical Holdings (4886) · FactFirst stated

Revenue and Profit Growth in the Cumulative Second Quarter of FY2023

First written in FY2024-Q2. . Latest entry: FY2024-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Trends in performance and profitability, including growth and changes in revenue and profitA theme 623 companies write about · 47 as a headwind · 766 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 126 companies compared. The sentences above are computed from all 126.Comparing 200 of the theme's 902 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q2First statedAnnual report

    「売上高 30,172 31,648 1,475 4.9% 営業利益 2,879 3,055 176 6.1% 経常利益 2,987 3,096 108 3.6% 親会社株主に帰属する 四半期純利益 2,346 4,129 1,783 76.0%」

    2023年度第2四半期連結累計期間は、売上高31,648百万円（前年同期比4.9％増）、営業利益3,055百万円（同6.1％増）、経常利益3,096百万円（同3.6％増）、親会社株主に帰属する四半期純利益4,129百万円（同76.0％増）となった。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.